T2 Biosystems (TTOO) Receiving Somewhat Negative News Coverage, Report Finds

News headlines about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat negative on Saturday, Alpha One reports. The research group, a division of Accern, rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a daily sentiment score of -0.25 on Alpha One’s scale. Alpha One also gave news stories about the medical equipment provider an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Alpha One Sentiment’s analysis:

T2 Biosystems (NASDAQ:TTOO) opened at 3.36 on Friday. The firm’s market capitalization is $102.80 million. T2 Biosystems has a 12-month low of $3.02 and a 12-month high of $9.26. The company’s 50-day moving average price is $3.80 and its 200-day moving average price is $5.09.

T2 Biosystems (NASDAQ:TTOO) last released its earnings results on Tuesday, May 2nd. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.55 million. T2 Biosystems had a negative return on equity of 134.73% and a negative net margin of 1,250.59%. Equities analysts expect that T2 Biosystems will post ($1.90) EPS for the current fiscal year.

A number of research analysts recently issued reports on TTOO shares. Zacks Investment Research raised T2 Biosystems from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. Canaccord Genuity set a $9.00 target price on T2 Biosystems and gave the stock a “buy” rating in a report on Tuesday, February 14th. Cantor Fitzgerald set a $7.00 target price on T2 Biosystems and gave the stock a “buy” rating in a report on Wednesday, March 8th. BTIG Research raised T2 Biosystems from a “sell” rating to a “neutral” rating and set a $4.00 target price on the stock in a report on Monday, May 8th. Finally, Morgan Stanley lowered T2 Biosystems from an “equal weight” rating to an “underweight” rating and set a $5.00 target price on the stock. in a report on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $6.75.

WARNING: “T2 Biosystems (TTOO) Receiving Somewhat Negative News Coverage, Report Finds” was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.mideasttime.com/t2-biosystems-ttoo-receiving-somewhat-negative-news-coverage-report-finds/1768700.html.

In other news, Director David B. Elsbree bought 10,000 shares of the company’s stock in a transaction dated Tuesday, June 6th. The stock was bought at an average price of $3.50 per share, for a total transaction of $35,000.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $175,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have bought 30,000 shares of company stock valued at $130,030. 43.20% of the stock is currently owned by corporate insiders.

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TTOO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for T2 Biosystems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.